CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-27 | COLLIER EARL M JR Director | Option exercise · Stock Option (Right to Buy) | −750 | 0 | ||
| 2025-01-02 | Litvack Frank Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-01-02 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award | +3,342 | 5,723 | ||
| 2025-01-02 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2025-01-02 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +6,170 | 6,170 | ||
| 2025-01-02 | Krasney Karen EVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-01-02 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2025-01-02 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +34,962 | 34,962 | ||
| 2025-01-02 | Kelliher Mike Director | Grant or award · Stock Option (Right to Buy) | +11,940 | 11,940 | ||
| 2025-01-02 | Kelliher Mike Director | Grant or award · Stock Option (Right to Buy) | +1,440 | 1,440 | ||
| 2025-01-02 | Kelliher Mike Director | Grant or award · Stock Option (Right to Buy) | +5,750 | 5,750 | ||
| 2025-01-02 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +11,940 | 11,940 | ||
| 2025-01-02 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +1,440 | 1,440 | ||
| 2025-01-02 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +5,750 | 5,750 | ||
| 2025-01-02 | Sabar Karimah Es Director | Grant or award · Stock Option (Right to Buy) | +11,940 | 11,940 | ||
| 2025-01-02 | Sabar Karimah Es Director | Grant or award · Stock Option (Right to Buy) | +2,520 | 2,520 | ||
| 2025-01-02 | Sabar Karimah Es Director | Grant or award · Stock Option (Right to Buy) | +5,750 | 5,750 | ||
| 2025-01-02 | Musket David B Director | Grant or award · Stock Option (Right to Buy) | +11,940 | 11,940 | ||
| 2025-01-02 | Musket David B Director | Grant or award · Stock Option (Right to Buy) | +6,480 | 6,480 | ||
| 2025-01-02 | Musket David B Director | Grant or award · Stock Option (Right to Buy) | +5,750 | 5,750 |
Page 5 of 24 · 468 trades